Management of a major varicella zoster exposure in a pediatric oncology population
Carol Rossetto,Kent Sepkowitz,Jill Ackerman,Rachel Corke,Nina J Pickett,Wini Cudjoe,Janet Eagan,Mini Kamboj,Richard J O'Reilly,Farid Boulad,Carol RossettoKent SepkowitzJill AckermanRachel CorkeNina J. PickettWini CudjoeJanet EaganMini KambojRichard J. O'ReillyFarid Boulada Department of Pediatrics,Memorial Sloan Kettering Cancer Center,New York,New York,USAb Division of Quality and Safety,Memorial Sloan Kettering Cancer Center,New York,New York,USAc Hospital Administration,Memorial Sloan Kettering Cancer Center,New York,New York,USAd Ronald McDonald House,New York,New York,USAe Infection Control,Memorial Sloan Kettering Cancer Center,New York,New York,USA
DOI: https://doi.org/10.1080/08880018.2024.2315456
2024-02-22
Pediatric Hematology and Oncology
Abstract:Management of the exposure of pediatric oncology patients to varicella zoster virus (VZV) is controversial. We report the exposure of 56 patients to a single child with chicken pox at a pediatric cancer housing facility and describe our strategic approach for their management. We reviewed the immune and clinical status of 56 children with cancer receiving ongoing treatment at Memorial Sloan Kettering Cancer Center (MSK) who, while living at a pediatric cancer housing facility, were exposed to the index patient. The management of patients exposed included: (1) determination of immune status, (2) availability of vaccination history or VZV disease prophylaxis, (3) exposure status and subsequent isolation during the period of incubation, and (4) VZV disease prophylaxis. In addition to the 56 patients exposed to the index case, eight children with cancer treated at other facilities and 11 healthy siblings living in the facility were exposed. Of the 56 MSK patients, 21 were classified as immunosuppressed and received varicella zoster immune globulin (human), intravenous standard immune globulin, or acyclovir based on serostatus and immune function. The cohort was followed for 4 weeks after the exposure and no secondary infections were diagnosed. We performed a risk assessment and created a management plan to control and prevent further exposure and development of disease. No secondary cases developed. This strategic approach could serve as a model for the management of VZV exposure for other pediatric oncology centers.
oncology,pediatrics,hematology